Pull to refresh
Logo
Daily Brief
Following Why Sign Up
CC

Craig M. Crews

Yale chemistry professor; founder of Arvinas

Appears in 1 story

Notable Quotes

Crews has long described PROTACs as turning a drug from a 'jammed key' into a 'demolition crew' — one molecule can destroy many copies of a target protein.

Stories

FDA approves first protein-destroying PROTAC drug for advanced breast cancer

New Capabilities

Vindicated after a 25-year scientific bet

For 25 years, drug companies have tried to design medicines that don't just block harmful proteins but destroy them outright. On May 1, the U.S. Food and Drug Administration (FDA) approved the first one. VEPPANU, developed by biotech Arvinas and Pfizer, treats a hard-to-treat form of metastatic breast cancer by hijacking the cell's own garbage-disposal system to shred a mutated estrogen receptor that fuels the tumor.

Updated Yesterday